Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David F. Busch is active.

Publication


Featured researches published by David F. Busch.


The New England Journal of Medicine | 1989

Acyclovir-Resistant Herpes Simplex Virus Infections in Patients with the Acquired Immunodeficiency Syndrome

Kim S. Erlich; John Mills; Pamela A. Chatis; Gregory J. Mertz; David F. Busch; Stephen E. Follansbee; Robert M. Grant; Clyde S. Crumpacker

RECURRENT herpes simplex virus (HSV) infections are frequent in patients with the acquired immunodeficiency syndrome (AIDS). Although they are usually self-limiting in the normal host, such infecti...


The New England Journal of Medicine | 1990

Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial.

Gifford S. Leoung; David W. Feigal; A. B. Montgomery; K. Corkery; L. Wardlaw; M. Adams; David F. Busch; Shelley M. Gordon; Mark A. Jacobson; Paul A. Volberding; DonaldI. Abrams

BACKGROUND AND METHODS Pneumocystis carinii pneumonia (PCP) is the most frequent life-threatening opportunistic infection associated with human immunodeficiency virus (HIV) infection. To assess the possible value of aerosolized-pentamidine prophylaxis in different doses, a controlled clinical trial was begun in 1987 with 408 subjects at 12 treatment centers. The participants were randomly assigned to receive 30 mg of pentamidine every two weeks, 150 mg every two weeks, or 300 mg every four weeks. RESULTS Eighteen months after randomization, the subjects in the 300-mg arm had had 8 confirmed episodes of PCP while receiving treatment, as compared with 22 in the 30-mg arm (P = 0.0008). The 150-mg arm had intermediate results but ones not significantly different from those of the 300-mg arm. Participants with previous episodes of PCP and CD4-cell counts less than 200 per cubic millimeter were at the highest risk for PCP. CONCLUSIONS Aerosolized pentamidine was effective for prophylaxis against PCP in patients infected with HIV, according to the dose and schedule of administration. It and zidovudine were well tolerated together and had independent prophylactic benefits.


Annals of Internal Medicine | 1982

An Outbreak of Pneumocystis carinii Pneumonia in Homosexual Men

Stephen E. Follansbee; David F. Busch; Constance B. Wofsy; Diana Lewis Coleman; John Gullet; Gerard P. Aurigemma; Thomas Ross; W. Keith Hadley; W. Lawrence Drew

Pneumocystis carinii pneumonia has rarely been reported in previously healthy persons over the age of 6 months. Five cases of P. carinii pneumonia in adult homosexual men, confirmed by biopsy results, are reported. All five patients were seropositive when tested for antibodies to cytomegalovirus and four had evidence of active concurrent cytomegalovirus infections. Kaposis sarcoma was shown in two of the patients and one had possible Pneumocystis infection of the central nervous system as well as P. carinii pneumonia. Three patients had second episodes of Pneumocystis pneumonia. Four of the five patients have died. Past or concurrent cytomegalovirus infection and homosexuality were the only common epidemiologic features in all five patients.


Antimicrobial Agents and Chemotherapy | 1976

Susceptibility of Respiratory Tract Anaerobes to Orally Administered Penicillins and Cephalosporins

David F. Busch; Lubna Afzal Kureshi; Vera L. Sutter; Sydney M. Finegold

Anaerobic bacteria recovered from airway-related infections were tested by agar dilution against selected penicillins and cephalosporins available for oral administration. Against 136 isolates, penicillins G and V showed comparable activity, particularly when pharmacological differences were considered. Although many isolates were exquisitely susceptible to the penicillins, only 55% of the Bacteroides species and 72% of all isolates were inhibited at 0.5 μg of penicillin G per ml. Results for penicillin V at 1 μg/ml were similar (59 and 73%). The two cephalosporins were more active at achievable levels, inhibiting 94 to 95% of Bacteroides and 95 to 96% of all isolates at 8 μg/ml. These levels represent approximately 50% of the reported peak serum levels after oral administration of 625 mg of the penicillins and 500 mg of the cephalosporins. Dicloxacillin and nafcillin were tested against 50 isolates. The two were comparably active on a weight basis; dicloxacillin was more active when pharmacological differences were considered, but did not match the other penicillins or the cephalosporins.


Antimicrobial Agents and Chemotherapy | 1977

Cefoxitin: Clinical Evaluation in Thirty-Eight Patients

Peter N. R. Heseltine; David F. Busch; Richard D. Meyer; Sydney M. Finegold

Clinical and bacteriological efficacy, patient tolerance, and toxicity of cefoxitin, a beta-lactamase-resistant cephamycin, were evaluated in 38 patients; 13 had soft tissue infection, 12 had pneumonia, 3 had urinary tract infection, 2 had peritonitis, and 4 had miscellaneous infections. In five patients, infection was clinically evident, though not bacteriologically proven. The latter patients were evaluated with regard to tolerance and toxicity only. Among the 34 infections in 33 patients, 71% were considered clinically cured; 86% of those patients who could be recultured were bacteriologically cured. Phlebitis was noted in 32% of the total group, and eosinophilia was observed in 16%. Unexplained deterioration in renal function occurred in two patients. Mean peak cefoxitin levels in serum were 72 μg/ml 30 min after a 2-g infusion and 32 μg/ml 30 min after a 1-g infusion. Cefoxitin was more active against facultatively and obligately anaerobic gram-negative organisms isolated from these patients than was cephalothin.


Annals of Internal Medicine | 1989

Intravascular and pleural involvement by Pneumocystis carinii in a patient with the acquired immunodeficiency syndrome (AIDS)

Toby Dyner; William Lang; David F. Busch; Phillip R. Gordon

Excerpt To the Editor:WhereasPneumocystis cariniipneumonia is common in patients with human immunodeficiency virus (HIV) infection, pleural and extrapulmonary infection have been thought to be rare...


The Journal of Infectious Diseases | 1991

Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection

W. Lawrence Drew; Richard C. Miner; David F. Busch; Stephen E. Follansbee; John Gullett; Steven G. Mehalko; Shelly M. Gordon; William F. Owen; Thomas R. Matthews; William Buhles; Bernadette DeArmond


The Journal of Infectious Diseases | 1993

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Cytomegalovirus Peripheral Retinitis in Patients with AIDS

Stephen A. Spector; Thomas A. Weingeist; Richard B. Pollard; Douglas T. Dieterich; Tobias Sarno; Constance A. Benson; David F. Busch; William R. Freeman; Paul R. Montague; Henry J. Kaplan; Lois Kellerman; Michael Crager; Bernadette De Armond; William Buhles; Judith Feinberg


The Journal of Infectious Diseases | 1995

Pharmacokinetic, Safety, and Antiviral Profiles of Oral Ganciclovir in Persons Infected with Human Immunodeficiency Virus: A Phase I/II Study

Stephen A. Spector; David F. Busch; Stephen E. Follansbee; Kathryn Squires; Jacob Lalezari; Mark A. Jacobson; James D. Connor; Donald Jung; Anna Shadman; Barbara Mastre; William Buhles; W. Lawrence Drew


The Journal of Infectious Diseases | 1993

Ganciclovir Treatment of Cytomegalovirus Colitis in AIDS: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study

Douglas T. Dieterich; Donald P. Kotler; David F. Busch; Clyde S. Crumpacker; Charles Du Mond; Bernadette Dearmand; William Buhles

Collaboration


Dive into the David F. Busch's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephen E. Follansbee

California Pacific Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Clyde S. Crumpacker

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Douglas T. Dieterich

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vera L. Sutter

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge